Literature DB >> 7906293

Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters.

P Aukrust1, N B Liabakk, F Müller, E Lien, T Espevik, S S Frøland.   

Abstract

Two EIAs (Medgenix and Quantikine) and a bioassay were used to measure tumor necrosis factor-alpha (TNF alpha) in serum samples from 73 human immunodeficiency virus type 1 (HIV-1)-seropositive patients and in samples from 2 control groups. All clinical groups of HIV-1-infected patients, regardless of concurrent illness, had significantly elevated levels of both types of soluble TNF receptors (sTNFRs) and immunoreactive TNF alpha (Medgenix EIA), with the highest concentrations among the AIDS patients. These TNF parameters were significantly correlated with reduced CD4+ lymphocyte counts. Only a few HIV-1-infected patients had detectable TNF alpha levels measured by the Quantikine EIA. TNF alpha bioactivity was significantly raised only in the AIDS group. Serially measured sTNFRs, expressed as sTNFR slopes, were significantly associated with survival in the patient group. The raised levels of immunoreactive TNF alpha and sTNFRs strongly indicate activation of the TNF alpha system during HIV-1 infection. Levels increase with disease progression and degree of immunodeficiency; thus, serially measured sTNFRs may give useful prognostic information in HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7906293     DOI: 10.1093/infdis/169.2.420

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  64 in total

1.  Highly active antiretroviral therapy (HAART) and circulating markers of immune activation: specific effect of HAART on neopterin.

Authors:  N Amirayan-Chevillard; H Tissot-Dupont; Y Obadia; H Gallais; J L Mege; C Capo
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

2.  Th1/Th2 cytokine profile in patients coinfected with HIV and Leishmania in Brazil.

Authors:  Maria Zilma Andrade Rodrigues; Maria Fernanda Rios Grassi; Sanjay Mehta; Xing-Quan Zhang; Luana Leandro Gois; Robert T Schooley; Roberto Badaro
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

3.  Is There a Potential Role for Anti-tumor Necrosis Factor Therapy in Patients with Human Immunodeficiency Virus?

Authors:  Jason J Emer
Journal:  J Clin Aesthet Dermatol       Date:  2009-04

4.  Responsiveness of muscle protein synthesis to growth hormone administration in HIV-infected individuals declines with severity of disease.

Authors:  M A McNurlan; P J Garlick; R T Steigbigel; K A DeCristofaro; R A Frost; C H Lang; R W Johnson; A M Santasier; C J Cabahug; J Fuhrer; M C Gelato
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

5.  IL-10 in HIV infection: increasing serum IL-10 levels with disease progression--down-regulatory effect of potent anti-retroviral therapy.

Authors:  E Stylianou; P Aukrust; D Kvale; F Müller; S S Frøland
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

6.  Bone mass and mineral metabolism in HIV+ postmenopausal women.

Authors:  Michael Yin; Jay Dobkin; Karen Brudney; Carolyn Becker; Janis L Zadel; Monica Manandhar; Vicki Addesso; Elizabeth Shane
Journal:  Osteoporos Int       Date:  2005-03-08       Impact factor: 4.507

7.  Influence of hepatitis C virus coinfection on failure of HIV-infected patients receiving highly active antiretroviral therapy to achieve normal serum beta2microglobulin levels.

Authors:  J A García-García; J A Mira; J Fernández-Rivera; A J Ramos; J Vargas; J Macías; J A Pineda
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-01       Impact factor: 3.267

8.  Circulating monocytes in HIV-1-infected viremic subjects exhibit an antiapoptosis gene signature and virus- and host-mediated apoptosis resistance.

Authors:  Malavika S Giri; Michael Nebozyhn; Andrea Raymond; Bethsebah Gekonge; Aidan Hancock; Shenoa Creer; Calen Nicols; Malik Yousef; Andrea S Foulkes; Karam Mounzer; Jane Shull; Guido Silvestri; Jay Kostman; Ronald G Collman; Louise Showe; Luis J Montaner
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

9.  High plasma level of soluble tumor necrosis factor receptor type II (sTNFRII) in asymptomatic HIV-1-infected patients.

Authors:  D Hober; S Benyoucef; A S Delannoy; D de Groote; F Ajana; Y Mouton; P Wattré
Journal:  Infection       Date:  1996 May-Jun       Impact factor: 3.553

10.  Tumor-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic viral infection.

Authors:  Marc Beyer; Zeinab Abdullah; Jens M Chemnitz; Daniela Maisel; Jil Sander; Clara Lehmann; Yasser Thabet; Prashant V Shinde; Lisa Schmidleithner; Maren Köhne; Jonel Trebicka; Robert Schierwagen; Andrea Hofmann; Alexey Popov; Karl S Lang; Annette Oxenius; Thorsten Buch; Christian Kurts; Mathias Heikenwalder; Gerd Fätkenheuer; Philipp A Lang; Pia Hartmann; Percy A Knolle; Joachim L Schultze
Journal:  Nat Immunol       Date:  2016-03-07       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.